Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Cellectis (NASDAQ:CLLS) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03), Zacks reports. Cellectis had a negative return on equity of 78.25% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. During the same period in the previous year, the business earned ($0.31) EPS.

Cellectis Stock Down 2.3 %

CLLS traded down $0.04 during trading on Thursday, reaching $1.73. The company’s stock had a trading volume of 51,171 shares, compared to its average volume of 48,834. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The company’s fifty day moving average price is $2.07 and its 200-day moving average price is $2.27. Cellectis has a 52-week low of $1.73 and a 52-week high of $3.77.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. StockNews.com began coverage on shares of Cellectis in a research report on Tuesday. They set a “sell” rating for the company. Barclays lowered their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.